Template:HSV-1 antiviral treatment: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
''Treatment does not affect dormant virus in nerve ganglions → recurrent disease remains possible'' | ''Treatment does not affect dormant virus in nerve ganglions → recurrent disease remains possible'' | ||
*Antiviral drug | *Antiviral drug options: | ||
**[[Acyclovir]] 40-80mg/kg PO divided in 3-4 doses for 5-7 days | **[[Acyclovir]] 40-80mg/kg PO divided in 3-4 doses for 5-7 days | ||
***Can also be used as a cream or oral suspension (swish and swallow)<ref name="Mohan" /> | ***Can also be used as a cream or oral suspension (swish and swallow)<ref name="Mohan" /> | ||
**[[Valacyclovir]] (significantly higher bioavailability than acyclovir) | **[[Valacyclovir]] (significantly higher bioavailability than acyclovir) | ||
**[[Famciclovir]] | **[[Famciclovir]] | ||
Revision as of 21:27, 25 April 2016
Treatment does not affect dormant virus in nerve ganglions → recurrent disease remains possible
- Antiviral drug options:
- Acyclovir 40-80mg/kg PO divided in 3-4 doses for 5-7 days
- Can also be used as a cream or oral suspension (swish and swallow)[1]
- Valacyclovir (significantly higher bioavailability than acyclovir)
- Famciclovir
- Acyclovir 40-80mg/kg PO divided in 3-4 doses for 5-7 days
- ↑ Cite error: Invalid
<ref>tag; no text was provided for refs namedMohan